Archive by year:

20 February 2015

Alethia Biotherapeutics Submits a Clinical Trial Application (CTA) for a Phase I Study with AB-16B5, an Inhibitor of EMT in Patients with Advanced Cancers

Alethia Biotherapeutics Inc., a privately held biotechnology company, announced that it has submitted a Clinical Trial Application (CTA) with Health Canada to initiate a Phase I clinical trial with AB-16B5, a fully humanized monoclonal antibody that inhibits epithelial to mesenchymal transition (EMT)

News 1 - 1 of 5
First | Prev. | 1 2 3 4 5 | Next | Last All